Skip to main content
SpringerLink
Log in

Antithrombotic Therapy

  • Chapter
Book cover Current Cardiovascular Drugs

  • 135 Accesses

Abstract

Antiplatelet agents prevent platelets from adhering to damaged vessel wall or to one another, a vital step in the Initiation of clot formation, particularly in arteries. Anticoagulant therapy is used to prevent clots from forming or extending by inhibiting the formation of the fibrin framework of the blood clot. Thrombolytic therapy activates the enzyme pathways that lyse the fibrin meshwork of the blood dot to restore blood flow after a dot has blocked a vessel. Figure 6.1 shows the clotting process cascade.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected Bibliography

  • ACC-AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: A report from the American College of Cardiology/American Heart Association: Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardinl 1996, 28: 1328–1428.

    Article  Google Scholar 

  • AIMS Trial Study Group: Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet 1990, 335: 427–431.

    Article  Google Scholar 

  • Albers GW, Sherman DG, Gress DR, et al.: Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neural 1991, 30: 511–518.

    Article  CAS  Google Scholar 

  • Amiral J, Bridey F, Wolf M. et al.: Antibodies to marcomolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromh Haemost 1995, 73: 21–28.

    CAS  Google Scholar 

  • Anderson JL: Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent. J Am Coll Cardiol 1987, 10: 22B - 27B.

    Article  PubMed  CAS  Google Scholar 

  • Antiplatelet Trialists Collaboration: Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br J Med 1994, 308: 81–106.

    Article  Google Scholar 

  • Antman EM, Guigliano RP, Gibson CM, et al. For the TIMI 14 Investigators: Abciximab facilitates the rate and extent of thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. Circulation 1999, 99: 2720–2732.

    Article  PubMed  CAS  Google Scholar 

  • Armstrong PW: Heparin in acute coronary disease: requiem for a heavyweight ‘editorial]. N Eng! J Med 1997, 337: 492.

    Article  CAS  Google Scholar 

  • Bode C, Smalling R, Gunther B, et al.: Randomized comparison of coronary thrombolysis achieved with double bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996, 94: 891–898.

    Article  PubMed  CAS  Google Scholar 

  • Cannon CP: Aggrastat in the treatment of unstable angina. Curr Pract Med 1998, 1: 55–58.

    Google Scholar 

  • CAPRIE Steering Committee: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348: 1329–1339.

    Article  Google Scholar 

  • CAPTURE Investigators: Randomised. placebo-controlled trial of abciximab before, during and after coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997, 349: 1429–1435.

    Article  Google Scholar 

  • Challapalli R, Lefkovits J, Topol EJ: Clinical trials of recombinant hirudin in acute coronary syndromes. Coronary Artery Disease 1996, 7: 429–437.

    Article  PubMed  CAS  Google Scholar 

  • Cohen M, Demers C, Gurfinkel E, et al. for the Efficacy and Safety of Subcutaneous Enoxaparin vs Non-Q-Wave Coronary Events Study Group: A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997, 337: 447–452.

    Article  PubMed  CAS  Google Scholar 

  • Collen D: Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation 1996, 93: 857–865.

    Article  PubMed  CAS  Google Scholar 

  • Danhof M, de Boer A, Magnani HN, et al.: Pharmacokinetic considerations of orgaran (org 10172) therapy. Haemostasis 1992, 22: 73–84.

    PubMed  CAS  Google Scholar 

  • EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptorin high-risk coronary angioplasty. N Engl J Med 1994, 330: 956–961.

    Article  Google Scholar 

  • EPILOG Investigators: Platelet glycoprotein Ilb/Isla receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med 1997, 336: 1689–1696.

    Article  Google Scholar 

  • EPISTENT Investigators: Randomised, placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998, 352: 87–92.

    Article  Google Scholar 

  • ESSENCE trial results: Breaking new ground: efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events. Can J Cardiol 1998, 14 (suppl E): 15–19

    Google Scholar 

  • Fifth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1998, 114 (suppl): 439S - 769S.

    Article  Google Scholar 

  • Forman R, Frishman WH: Thrombolytic agents. In Cavascular Pharmacotherapeutics. Edited by Frishman WH, Sonnenblick EH. New York: McGraw Hill; 1997: 38l - 398.

    Google Scholar 

  • Foster RH, Wiseman LR: Abciximab: an updated review of its use in ischaemic heart disease. Drugs 1998, 56: 629–66

    Article  PubMed  CAS  Google Scholar 

  • Frishman WH, Klein MD, Blaufarb I, et al.: Antiplatelet an other antithmmbotic drugs. In Cardiovascular Pharmacot herapeutics. Edited by Frishman WH, Sonnenblick New York: McGraw Hill; 1997: 323–379.

    Google Scholar 

  • Gent M, Easton JD, Hachinski VC, et al.: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989, 1: 1215–1220.

    Article  PubMed  CAS  Google Scholar 

  • GISSI (Gruppo Italiano per to Studio della Streptochinasi nel1’Infarcto Miocardico): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986. 1: 397–401.

    Google Scholar 

  • GISSI Group, GISSI 2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patient with acute myocardial infarct Lancet 1990, 336: 65–71.

    Google Scholar 

  • Glycoprotein (GP) llb/Illa Inhibitors in Acute Coronary Syndromes: Applying Evidence from Clinical Trials to Medical Practice. Data presented concurrently with the 48th Annual Scientific Session of the American College of Cardiology, March 6, 1999: New Orleans, Louisiana. Presentations in FocusTM, supported by an education grant from COR Therapeutics Inc. and Key Pharmaceuticals Inc.. 1999.

    Google Scholar 

  • Granger CB, Califf RM, Topol El: Thrombolytic therapy for acute myocardial infarction. Drugs 1992, 44: 293–325.

    Article  PubMed  CAS  Google Scholar 

  • Greinacher A, Alban S: Heparinoids as alternative for par-enteral anticoagulation therapy in patients with heparin-induced thmmbocytopenia. Hamostaseologie 1996, 16: 41–49.

    CAS  Google Scholar 

  • Greinacher A, Amiral J, Dummel V, et al.: Laboratory diagnosis of heparin-associated thrombo-cytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4-heparin enzyme linked immunosorbent assay. Transfusion 1994, 34: 381–385.

    Article  PubMed  CAS  Google Scholar 

  • Greinacher A, Volpel H, Janssens U, et al.: Recombinent hirudin provides safe and effective anti-coagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999, 99: 73–80.

    Article  PubMed  CAS  Google Scholar 

  • Grotta JC, Norris JW, Kamm B: Prevention of stroke with ticlopidine: who benefits the most’? TASS baseline and angiographic subgroup. Neurology 1992, 42: 111–115.

    Article  PubMed  CAS  Google Scholar 

  • GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993, 329: 673–682.

    Article  Google Scholar 

  • Hass WK, Easton JD, Adams HP. et al.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989, 321: 501.

    Article  PubMed  CAS  Google Scholar 

  • Hennekens CH, O’Donnell CJ, Ridker PM, et al.: Current issues concerning thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1995, 25 (suppl): 18s - 22s.

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J, Fuster V: Guide to anticoagulant therapy. Part I: heparin. Circulation 1994, 89: 1449–1468.

    Article  PubMed  CAS  Google Scholar 

  • Hirsh I, Fuster V: Guide to anticoagulant therapy. Part 2: Oral anticoagulants. Circulation 1994, 89: 1469–1493.

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J, Raschke R, Warkentin TE, et al.: Heparin: mechanism of action. pharmacokinetics dosing considerations, monitoring. efficacy and safety. Chest 1995, 108: 2585–2755.

    Google Scholar 

  • Hirsh J, Warkentin TE, Raschke R. et al.: Heparin and lowmolecular-weight heparin: mechanisms of actions, pharmacokinetics, dosing consideration, monitoring, efficacy and safety. Chest 1998, 114 (suppl): 489s - 510s.

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J: Low-molecular-weight heparin: a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 1998, 98: 1575–1582.

    Article  PubMed  CAS  Google Scholar 

  • IMPACT II Investigators: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997, 349: 1422–1428.

    Article  Google Scholar 

  • INJECT Study Group: Randomised. double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995, 346: 329–336.

    Article  Google Scholar 

  • ISIS 2 Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin. both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988, 2: 349–360.

    Google Scholar 

  • ISIS-3: A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41.299 cases of suspected acute myocardial infarction. Lancet 1992, 339: 753–770.

    Article  Google Scholar 

  • Jang I-K, Brown DFM, Giugliano RP, et al and the MINT Investigators: A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial Infarction with Novastatin and TPA (MINT) Study. J Am Coll Cardiol 1999, 33: 1879–1885.

    Article  PubMed  CAS  Google Scholar 

  • Krumholz HM, Pasternak RC, Weinstein MC, et al.: Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute tyocardial infarction. N Engl J Med 1992, 327: 7–13.

    Article  PubMed  CAS  Google Scholar 

  • Levine M, Gent M, Hirsh J. et al.: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996, 334: 677–681.

    Article  PubMed  CAS  Google Scholar 

  • McEwen J, Strauch G, Perles P. et al.: Clopidogrel bioavailability is unaffected by food or antacids. J Clin Pharmacol 1996, 36: 856.

    Google Scholar 

  • Monealescot G, Phillippe F, Ankri A. et al.: Early increase in von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Circulation 1998, 98: 294–299.

    Article  Google Scholar 

  • Monreal M, Costa J, Salva P: Pharmacological properties of hirudin and its derivatives: potential clinical advantages over heparin. Drugs Aging 1996, 8: 171–182.

    Article  PubMed  CAS  Google Scholar 

  • Noble S, Spencer CM: Enoxaparin: a review of its clinical potential in the management of coronary artery disease. Drugs 1998, 56: 259–272.

    Article  PubMed  CAS  Google Scholar 

  • Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators: Effects of recombinant hirudin (lepirudin) compared with heparin on death. myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999, 353: 429–438.

    Article  Google Scholar 

  • Patrono C: Aspirin as an antiplatelet agent. N Engl J Med 1994, 329: 1287–1294.

    Google Scholar 

  • Phillips DR, Scarborough RM: Clinical pharmacology of eptifibatide. Am J Cardiol 1997, 80: 11B - 20B.

    Article  PubMed  CAS  Google Scholar 

  • Pined GF, Hull RD: Unfractionated and low-molecularweight heparin: comparison and current recommendations. Med Clin North Am 1998, 82: 587–599.

    Google Scholar 

  • PRISM Study Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998, 338: 1498–1505.

    Article  Google Scholar 

  • PRISM-PLUS Study Investigators: Inhibition of platelet glycoprotein Ilb/llla receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998, 338: 1488–1497.

    Article  Google Scholar 

  • PURSUIT Trial Investigators: Inhibition of platelet glycopmtein Ilb/lila with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998, 339: 436–443.

    Article  Google Scholar 

  • RESTORE Investigators: Effects of platelet glycoprotein lIb/Illa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997, 96: 1445–1453.

    Article  Google Scholar 

  • Sallie E, Ward A: Ticlopidine: a review of its pharmacodynamic and phannacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987. 34: 222–262.

    Article  Google Scholar 

  • SCATI (Studio sulla Calciparina nell’ Angina e nella Trombosi Ventricolare nell Infarcto) Group: Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989, 2: 182–186.

    Google Scholar 

  • Sharis PI, Cannon CP, Loscalzo J: The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998, 129: 394–405.

    Article  PubMed  CAS  Google Scholar 

  • Smalling R, Bode C, Kalbfleisch J, et al.: More rapid. complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995, 91: 2725–2732.

    Article  PubMed  CAS  Google Scholar 

  • Smith P, Amesen H, Holme I: The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990, 323: 147–152.

    Article  PubMed  CAS  Google Scholar 

  • Stein B, Fuster V, Israel DH, et al.: Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol 1989, 14: 813–836.

    Article  PubMed  CAS  Google Scholar 

  • The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Eng! J Med 1991, 325: 1261–1266.

    Article  Google Scholar 

  • The ECASS Study Group: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 1995, 274: 1017–1025.

    Article  Google Scholar 

  • The European Myocardial Infarction Project Group: Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993, 329: 383–389.

    Article  Google Scholar 

  • The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators: A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997, 337: 1118–1123.

    Article  Google Scholar 

  • The National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Eng! J Med 1995, 333: 1581–1587.

    Article  Google Scholar 

  • The Steering Committee of the Physicians’ Health Study Research Group: final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989, 321:129–135.

    Google Scholar 

  • Theroux P, Ouimet H, McCars J, et al.: Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988, 319: 1105–1111.

    Article  PubMed  CAS  Google Scholar 

  • TIMI Study Group: Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: result of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989, 320: 618–627.

    Article  Google Scholar 

  • Verstraete M, Fuster V: Thrombogenesis and antithrombotic therapy. In Hurst’s The Heart, edn 9. Edited by Alexander RW, Schlant RC, Fuster V. New York: McGraw Hill; 1998: 1501–1551.

    Google Scholar 

  • Warkentin TE, Chong BH, Greinacher A: Heparin-induced thrombocytopenia: towards consensus. Thromb Haenwstas 1998, 79: 1–7.

    CAS  Google Scholar 

  • Warkentin TE, Elavathil U, Hayward CPM, et al.: The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997, 127: 804–812.

    Article  PubMed  CAS  Google Scholar 

  • Wilcox RG, Von der Lippe G, Olsson CG, et al.: Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction (ASSET). Lancet 1988, 2: 525–530.

    Article  PubMed  CAS  Google Scholar 

  • Wilde Ml, Markham A: Danaparoid: a review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997, 54: 903–924.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Westchester Medical Center, New York Medical College, Valhalla, New York, USA

    William H. Frishman M.D. (Professor of Medicine and Pharmacology, Chairman of Medicine, Director of Medicine)

  2. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA

    Angela Cheng-Lai Pharm.D. (Clinical Pharmacy Manager, Adult Medicine, Assistant Professor of Medicine) & Julie Chen Pharm.D., BCPS (Clinical Pharmacy Manager, Critical Care, Assistant Professor of Medicine)

Authors
  1. William H. Frishman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Angela Cheng-Lai Pharm.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julie Chen Pharm.D., BCPS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Westchester Medical Center, New York Medical College, Valhalla, New York, USA

    William H. Frishman M.D. (Professor of Medicine and Pharmacology, Chairman of Medicine, Director of Medicine) (Professor of Medicine and Pharmacology, Chairman of Medicine, Director of Medicine)

  2. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA

    Angela Cheng-Lai Pharm.D. (Clinical Pharmacy Manager, Adult Medicine, Assistant Professor of Medicine) & Julie Chen Pharm.D., BCPS (Clinical Pharmacy Manager, Critical Care, Assistant Professor of Medicine) (Clinical Pharmacy Manager, Adult Medicine, Assistant Professor of Medicine) &  (Clinical Pharmacy Manager, Critical Care, Assistant Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Frishman, W.H., Cheng-Lai, A., Chen, J. (2000). Antithrombotic Therapy. In: Frishman, W.H., Cheng-Lai, A., Chen, J. (eds) Current Cardiovascular Drugs. Current Medicine Group, London. https://doi.org/10.1007/978-1-4615-6767-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-6767-7_7

  • Publisher Name: Current Medicine Group, London

  • Print ISBN: 978-1-57340-135-7

  • Online ISBN: 978-1-4615-6767-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation